乳腺癌患者细胞外囊泡的特征
通过单分子检测阵列 (SiMoA) 数字 ELISA 表征乳腺癌患者血浆中的细胞外囊泡
Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from cells and mediators of intercellular cross-talk. In breast cancer (BC), EVs seem to be involved in the tumor microenvironment's shaping, in cancer cells invasion and in the set-up of metastasis.
Clinical studies have provided initial evidence that these vesicles may have a prognostic and predictive value in breast cancer. Considering their ubiquitous presence in body fluids and their minimally invasive assessment through blood sampling, EVs could have a potential as liquid biopsy-derived biomarkers. Their quantification though is a complex task requiring complicated and time-consuming pre-analytical procedures of EVs isolation.
This protocol want to develop a new method for the detection of tumor-derived-EVs associated proteins, based on the use of Single Molecule Array (SiMoA), a digital ELISA technology able to detect and quantify extremely low concentrations of target proteins or particles.
The aim of this study is to evaluate how this new technology can allow the quantification of EVs plasma levels in patients affected by BC, providing useful diagnostic and prognostic information.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
This is a prospective, observational, monocentric and no profit study. The study involves the analysis of plasma from patients with breast cancer in order to quantify and characterize tumor-derived EVs at specific disease stages.
The enrollment of consecutive patients affected by BC referring to an EUSOMA-accredited Breast Unit is planned.
The patients will be divided into three pre-planned groups, as follows:
Population 1: patients diagnosed with early breast cancer patients (stage I-III) with indication to curative surgery.
Population 2: a control group made of sex- and age-matched healthy volunteers, not affected by cancer or chronic diseases.
Population 3: patients with metastatic breast cancer diagnosis. For each patient a blood sample will be collected and plasma will be isolated. A new SiMoA assay based on the use of anti-CD63 and anti-CD9 antibodies, two well known protein markers of EVs, will be used to capture and quantify EVs directly from plasma without requiring any prior sample processing.
The study will be conducted following the International Conference on Harmonization [ICH] Good Clinical Practice [GCP] guidelines. The Ethical Committee of ICS Maugeri authorized the study as protocol 2490/2020.
研究类型
研究类型
注册 (估计的)
注册
联系人和位置
学习联系方式
学习联系方式
- 姓名:Fabio Corsi, Professor
- 电话号码:0382592272
- 邮箱:fabio.corsi@icsmaugeri.it
研究联系人备份
- 姓名:SARA PAOLA ALBASINI, MsC
- 电话号码:3497378405
- 邮箱:sara.albasini@icsmaugeri.it
学习地点
-
-
Lombardy
-
Pavia、Lombardy、意大利、27100
- 招聘中
- Istituti Clinici Scientifici Maugeri SpA
-
接触:
- Fabio Corsi, Professor
- 电话号码:0382592272
- 邮箱:fabio.corsi@icsmaugeri.it
-
接触:
- Sara Albasini, MsC
- 电话号码:3497378405
- 邮箱:sara.albasini@icsmaugeri.it
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Breast cancer patients
描述
Inclusion Criteria:
- Signing of a specific informed consent for participation to the study
- Female sex
Population 1:
- Diagnosis of early breast cancer;
- Indication for surgery after multidisciplinary discussion.
Population 2:
- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.
Population 3:
- Diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;
- Indication to chemotherapy.
Exclusion Criteria:
Population 1:
- Presence of distant metastases
- Synchronous presence of a different tumor
- Indication to neoadjuvant chemotherapy
Population 2:
- Diagnosis of breast cancer
- Synchronous presence of a different tumor or chronic disease
Population 3:
- Patients who are unfit for systemic chemotherapy treatment
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
团体/队列数
队列和干预
团体/队列团体/队列 |
干预/治疗干预/治疗 |
|---|---|
|
Early Breast Cancer patients
|
Analysis of plasma in order to quantify and characterize EVs |
|
Metastatic Breast Cancer patients
|
Analysis of plasma in order to quantify and characterize EVs |
|
Healthy patients
- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment. |
Analysis of plasma in order to quantify and characterize EVs |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
EVs levels in early BC
大体时间:36 months
|
Determination of plasma EVs levels in patients with EBC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls |
36 months
|
|
EVs levels in metastatic BC
大体时间:36 months
|
Determination of plasma EVs levels in patients with first diagnosis of metastatic BC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls |
36 months
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
EVs levels after surgery
大体时间:36 months
|
Determination of plasma EVs levels in patients with early BC one month after surgery and comparison with pre-surgery EVs levels in order to evaluate any qualitative of quantitative modifications in circulating EVs |
36 months
|
|
EVs levels after chemotherapy treatment
大体时间:36 months
|
Determination of plasma EVs levels in patients with first diagnosis of metastatic BC after 4 months of systemic therapy and comparison with pre-therapy EV's plasma levels |
36 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.